Vertex Pharmaceuticals Incorporated (VRTX) Stock

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is led by CEO Reshma Kewalramani, employs 6,100 people, headquartered in Boston, US, publicly traded since 1991.

Vertex Pharmaceuticals Incorporated (VRTX) stock trades at $523.93 with a market capitalization of $132.80B. The stock is valued at a price-to-earnings (P/E) ratio of 30.38, price-to-book of 6.60, price-to-sales of 10.58. Over the past 52 weeks the stock has ranged between $379.72 and $560.25, and currently trades 6.5% below its 52-week high.

On profitability, Vertex Pharmaceuticals Incorporated generates a return on equity (ROE) of 23.31%, above the typical market range of roughly 12-15%, return on capital employed of 20.74%, an operating margin of 39.43%, a net profit margin of 34.89%.

In its most recent fiscal year, Vertex Pharmaceuticals Incorporated reported annual revenue of $12.1B, net profit of $4.0B. Over the last 5 fiscal years, revenue grew at an average annual rate of 14.2%, and net profit grew at an average annual rate of 7.8%.

The balance sheet shows a debt-to-equity ratio of 0.10 (debt below half of shareholders' equity), a current ratio of 2.90, total assets of $26.1B, $5.1B in cash and equivalents.

VRTX has a beta of 0.32 (historically less volatile than the overall market).

Vertex Pharmaceuticals Incorporated by the numbers, 2016–2025

Between 2016 and 2025 Vertex Pharmaceuticals Incorporated reported revenue of $1.7B rising to $12.1B, a change of +609.5% across 10 years. Compounded, revenue has grown 14.2% a year over five years, 10.6% over three, 9.6% over the last twelve months. Net profit rose to $4.0B.

Operating margin went from 0.6% in 2016 to 39.4% in 2025, a gain of 38.9 percentage points. The most recent net margin is 34.89%. On a trailing twelve-month basis to Jun '26, revenue is $12.6B and net profit $4.4B.

Borrowings rose from $841.0M to $3.9B, cash from operations was $3.6B in the latest year, positive in 9 of the last 10.

Return on equity has averaged 17.1% over five years, and was 21.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Vertex Pharmaceuticals Incorporated (VRTX) — frequently asked questions